DiaGenic ASA is an innovative Norwegian in vitro diagnostic company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly diagnostic tests for the early detection of devastating diseases where early intervention is crucial for successful treatment. DiaGenic's patented method is based on identifying disease-specific gene expression signatures from easily available sample material such as blood.

DiaGenic's first two products, ADtect® for early detection of Alzheimer's disease and BCtect® for early detection of breast cancer, have received regulatory approval for Europe, CE mark, and are now being launched in selected markets in Europe.

DiaGenic has an existing pipeline of projects focusing on discovery and documentation of gene expression signatures for Parkinson's Disease and for identification of patients with Mild Cognitive Impairment that will convert to Alzheimer's disease.

The company is a leader in discovery and development of diagnostic tests based on peripheral gene expression profiling.

The diagnostic tests together with an R&D cooperation with a major pharmaceutical company forms the basis of the company's biomarker strategy enabling early disease detection for clinical trials.